Procedure for the treatment of depression and Anxiety Disorders through Combination Therapy comprising a ligand alpha 2 Delta and an SSRI or SNRI and /

摘要

It provides a method of treatment of depression in a Mammal, including a human being, as well as Depression and a disease, disorder or condition simultaneously exemplified by, but not limited to, anxiety, Sleep Disorders and post-traumatic stress disorders.The Procedure involves the Administration to a Mammal an effective amount of a combination of Active Ingredients that include: a) a ligand alpha 2 Delta (A2D) or a prodrug thereof,Or a pharmaceutically acceptable Salt of the ligand or the A2D prodrug; and active agents selected from: (b) a selective serotonin reuptake inhibitor (SSRI (in English) or a prodrug thereof, or a pharmaceutically acceptable Salt of the SSRIs or d Icho prodrug; (c) A Selective inhibitor of the reuptake of noradrenaline (Abbreviated English sNRI) or a prodrug thereof, or a pharmaceutically acceptable Salt or prodrug of said SNRIs such mixtures; and (b) and (c).Also provided is a Pharmaceutical composition comprising a therapeutically effective amount of (a) an A2D ligand or a prodrug thereof, or a pharmaceutically acceptable Salt of the ligand or the A2D prodrug; and active agents selected from: (b) an SSRI P a pro The same Drug,Or a pharmaceutically acceptable Salt or prodrug of said that SSRIs; (c) an SNRI or a prodrug thereof, or a pharmaceutically acceptable Salt or prodrug of said SNRIs such mixtures; and (b) and (c). The preferred Active Ingredients for the treatment and Pharmaceutical composition include pregabalin, gabapentin, and Reboxetine sertraline.